ARTICLE |
Correspondence to: Nuzhat Ahmed, Gynaecological Cancer Research Centre, Royal Women's Hospital, 132 Grattan Street, Carlton, Victoria 3053, Australia. E-mail: nuzhata@unimelb.edu.au
![]() |
Summary |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The mechanism(s) responsible for the progression of non-metastatic or borderline ovarian cancer to invasive Grade I/III ovarian cancer is still unknown. An epithelium-restricted integrin, vß6, is present in malignant epithelia but not in normal epithelia. We studied the relative expression and distribution of
vß6 integrin in early and late-stage invasive (Grade I and Grade III) and non-invasive (benign and borderline) ovarian tumors of serous, mucinous, endometrioid, and clear-cell carcinoma subtypes, to assess its potential as a marker for epithelial ovarian cancer progression. Sixty-six specimens, including eight normal, 13 benign, 14 borderline, 13 Grade I, and 18 Grade III tumors were evaluated by immunohistochemistry (IHC) using a monoclonal antibody (MAb) against
vß6 integrin. Normal ovarian surface epithelium was negative for
vß6 integrin expression. All 45 carcinomas studied were positive, and the staining intensity significantly correlated with the grade of the tumor. The Grade III carcinomas of all types showed strong staining intensity. Only mucinous benign tissues were positive, and no reactivity was observed in benign serous neoplasms. On the basis of these observations, we hypothesize that the expression of
vß6 integrin is associated with epithelial ovarian cancer and that a gradual increase in the expression of the molecule may be a correlative index of the progression of this disease.
(J Histochem Cytochem 50:13711379, 2002)
Key Words:
vß6 integrin, epithelial cells, ovarian cancer, metastasis
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Ovarian carcinoma is the leading cause of gynecological cancer-related death (
Studies on normal and transformed cells have suggested that after malignant transformation striking changes occur in the ability of the cells to interact with their extracellular matrix (ECM) and other neighboring cells. Much interest in this respect has focused on the rapidly growing integrin family of cell surface receptors (- and ß-subunits, which are integrated across the plasma membrane to provide a link between the ECM and the cytoskeletal molecules in the cells. There are two major families of integrins. Those in which the ß1-chain combines with any one of nine
-chains and the
v group, in which the
v associates with either ß1-, ß3-, ß5-, ß6- or ß8-subunits. The variable unit in both groups determines the ECM ligand specificity (i.e., fibronectin, laminin, vitronectin, or tenascin) for individual receptors. In addition to their role in cell adhesion, the integrins are also believed to be involved in cell differentiation, gene expression, proliferation, and survival/apoptosis.
vß6 integrin is highly expressed in developing fetal tissues and in a number of epithelial carcinomas and cancer cell lines (
vß6 integrin plays a role in inflammation and wound healing through facilitation of the migration of epithelial cells to traumatized area and in the re-establishment of an intact epithelium at injured sites (
vß6 integrin has been demonstrated in colon and pancreatic carcinomas, whereas no such expression was found in normal epithelium of the same origin (
vß6 integrin in a range of epithelial neoplasms has been reported (
vß6 expression in breast and oral squamous carcinomas (
vß6 by transfection has also been reported to promote proliferation of colon cancer cells in vitro and increases tumor growth in nude mice (
vß6 integrin in cancer growth and progression. Hence, the available data concerning the role of
vß6 integrin support the hypothesis that overexpression of
vß6 integrin may initiate transformed cells towards a more malignant phenotype, partially through alterations in cell proteolytic activities frequently implicated in metastasis.
The purpose of this study was to examine the expression of vß6 integrin in the main subtypes of human epithelial ovarian cancer to evaluate its possible association with histological grade and tumor subtypes. Our results show that
vß6 expression is associated with ovarian cancer and that the expression of the integrin increases with advancing grade in all epithelial ovarian cancer subtypes. These data are consistent with the expression of
vß6 integrin in other epithelial cancers.
![]() |
Materials and Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The study was approved by Royal Women's Hospital, Melbourne Human Ethics Committee (HEC#99/32). Resected tissues not required for clinical analyses were obtained from patients who presented for surgery at the Oncology/Dysplasia Clinic at the Royal Women's Hospital, Melbourne, after the provision of participant information statements and only with informed consent. Normal ovaries needed for control comparisons were removed from patients undergoing surgery as a result of suspicious ultrasound images, palpable abdominal masses, and family history. The pathology diagnosis and tumor grade were determined from reports issued by the Department of Anatomical Pathology, Royal Women's Hospital, Melbourne.
The tissues were divided and frozen in cylinders of frozen section embedding medium (OCT) by immersion in isopentane cooled in dry ice. The tissues were then stored at -80C until needed. Frozen sections of the tissues were cut at 5-µm thickness and, if not used immediately, stored at -20C. For staining, sections were fixed in cold acetone for 15 min and held in Tris buffer (100 mM, pH 7.6). Endogenous peroxidase activity was removed using 3% H2O2 in methanol and endogenous biotin activity was blocked using a sequence of diluted egg white (5% in distilled water) and skim milk powder (5% in distilled water), all for 10 min each.
The sections were incubated for 1 hr in vß6 MAb (E7P6; Chemicon, Temecula, CA) diluted 1:200 in 1% BSA in Tris buffer (100 mM, pH 7.6). Antibody binding was amplified using biotin and streptavidin HRP (DAKO; Carpinteria, CA) for 15 min each and the complex was visualized using diaminobenzidine (DAB). Nuclei were lightly stained with Mayer's hematoxylin and the sections mounted and coverslipped. An isotype IgG1, suitably diluted, was substituted for the antibody as a negative control.
Sections were assessed microscopically for positive DAB staining by two trained pathologists. The degree of staining of vß6 expression was scored in a blind fashion as (-, 0%), (+, <20%), (++, 2050%) and (+++, >50%), corresponding to 0%, <20%, 2050%, and >50% of positive cells in tissue sections. The staining intensity was also scored as negative (0%), weak (<20%), moderate (2050%), and strong (>50%) immunoreactivity. From each tissue, four sections were studied and the percentage of staining was determined by an average number of positively stained cells in four sections. In addition to the type of staining, tissue and cell distribution of staining was determined. Percentage of tissues having weak, moderate, and strong staining in each particular grade and subtype was scored. Parallel frozen sections were stained with hematoxylin and eosin to confirm the pathological diagnosis. Both hematoxylin and eosin and immunostained sections were reviewed independently by two pathologists with 100% agreement on cell type, grade, and immunohistochemical score.
For statistical analysis, 2 analyses were used to test the association between the intensity of staining and the histological grade and subtype of tumor.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Fig 1 shows the hematoxylin and eosin staining of normal and Grade III ovarian tumors. Fig 1A shows a thin layer of normal ovarian surface epithelium that is altered and replaced by tumor cells in Grade III tumors (Fig 1B1E).
|
Normal Ovaries and Benign Serous Cystadenomas
No vß6 expression was observed in normal ovaries (n=8) or in benign ovarian serous cystadenomas (n=8) (Fig 2A and Fig 2B) (Table 1).
|
|
Borderline Serous Tumor (Tumors of Low Malignant Potential)
Eight patients with low-grade borderline ovarian cancer revealed weak (+) to moderate (++) vß6 expression (Fig 2C). Expression varied from strips of low profile cells with solid cytoplasmic staining to small groupings of cells and individual cells with paler, granular cytoplasmic staining. When more solid staining areas were present, these were associated with positive basement membrane staining. In some cases staining was confined to thin "endotheliumlike" cells.
Grade I/III Serous Ovarian Adenocarcinomas
Five cases of Grade I tumors were available for examination. Four cases showed some areas of staining (++) that were confined to short strips of strongly staining "endothelium-like" cells with associated basement membrane staining. One case showed extensive strong similar staining. Ten Grade III serous ovarian adenocarcinoma cases were examined and showed moderate (++) to strong (+++) expression of vß6 integrin (Fig 2 D). Staining was mostly cytoplasmic or granular, and varied in intensity. In many serous ovarian adenocarcinomas, cell membranes also exhibited strong (+++) staining. Positive staining ranged from involvement of the majority of tumor cells to only scattered positive cells.
Benign, Borderline, and Grade I Mucinous Ovarian Tumors
Fifteen mucinous tumors were examined. These included five benign cystadenomas, six borderline tumors, and four classified as Grade I mucinous adenocarcinomas. All benign tumors demonstrated positive staining that was unlike than that seen in the benign serous group (Fig 3A). Smaller endocervical-type cells were strongly positive, whereas taller columnar cells exhibited more diffuse perinuclear staining. The basement membrane was stained in some areas and the glycocalyx was strongly outlined in many columnar cells. Staining patterns in the borderline tumors were similar to those found in the benign group (Fig 3B). In the tall columnar cells, cytoplasmic staining was sparse and mostly perinuclear, but was also found along most of the intracellular borders. The four Grade I mucinous tumors showed similar staining patterns, with large numbers of the epithelial cells staining strongly positive (+++) (Fig 3C).
|
Grade I/III Endometrioid Tumors
Ten endometrioid ovarian tumors were studied. The four Grade I tumors exhibited weak (+) to moderate (++) staining, which consisted of diffuse cytoplasmic staining and basement membrane staining in areas adjacent to the main tumor mass. Five of six Grade III tumors were strongly positive (+++). Multiple nests of cells showed diffuse cytoplasmic staining that varied in intensity (Fig 4A). In many areas the intracellular membranes were highlighted and in some areas the basement membrane appeared to be involved. There were also some individual cells with cytoplasmic staining in stromal areas.
Clear-cell Carcinoma and Transitional-cell Carcinoma
Two other ovarian cancers were examined. One was a Grade III clear-cell carcinoma and the other was a bilateral ovarian tumor, one being a transitional-cell tumor and the other mixed tumor having transitional, serous, and clear-cell phenotype.
The clear-cell tumor contained many scattered positively staining cell groups. Some of this staining was cytoplasmic and some of it was outlining cell membranes (Fig 4B). The pure transitional-cell tumor was negative, and the mixed tumor showed some staining in areas with clear-cell differentiation.
None of the tissues showed any positive staining with IgG1 isotype control.
Statistical Analysis
Specimens from 45 epithelial ovarian cancers were evaluated. vß6 integrin was present in 100% of the cases. Of the 45 cases, 14 were borderline and 31 were malignant tumors. Data indicated highly significant
vß6 expression in malignant (Grade I/III) vs borderline tumors with
2 = 12.57 (p=0.01). Strong staining (+++) was present in 72% of Grade III tumors compared to only 28.5% of borderline tumors (Table 2). Weak staining, on the other hand, was present in 43% of borderline tumors vs 0% of Grade III tumors. Approximately 28% of Grade III, 46% of Grade I, and 28.5% of borderline tumors were moderately positive for
vß6 integrin (Table 2).
|
Intensity of staining was compared to the histological subtype of tumors (Table 3). Specimens were divided into three groups: serous (n=31), mucinous (n=15), and endometrioid (n=10). Statistical analysis revealed no significant differences in staining intensity among serous, endometrioid, and mucinous tumor subtypes with 2 = 6.84 (p=0.14) (Table 3).
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Ovarian cancer cells bind to various ECM constituents, but the integrin repertoire reported to date encompasses ß1 integrin in complex with other integrin subunits such as 1,
2,
3,
5, and
6 (
vß3 expression occurs at a significantly higher rate in advanced ovarian tumors than in tumors of low malignant potential (
vß3 integrin with grade and histology of ovarian tumors. It is possible that
vß3 functions as an angiogenesis factor in ovarian cancer, as suggested for breast cancer (
To date, the pathophysiology of the progression of ovarian cancer remains obscure. We have recently demonstrated the expression of vß6 integrin in ovarian cancer cell lines but not in normal ovarian cell lines (
vß6 integrin in ovarian cancer cell lines correlates with the invasive potential of the cells (e.g., secretion of proteases, degradation of radiolabelled ECM), consistent with the function of this integrin in other cancers (
vß6 integrin in neoplastic ovarian tissues but not in normal ovaries. Significant differences could be detected between the expression of
vß6 integrin in non-invasive borderline tumors and invasive Grade III ovarian tumors. Invasive Grade III ovarian tumors showed strong expression throughout the entire tumor, whereas non-invasive borderline tumors showed localized staining confined to epithelial cells at the edges. Restricted expression of
vß6 integrin in only neoplastic ovarian tissues may be important for cell migration and invasion because increased expression is found at the tips of migrating epithelial cells during wound healing (
Mucinous tumors had stronger expression of vß6 integrin compared to other categories of epithelial ovarian tumors. These tumors frequently exhibit microscopically an admixture of benign, borderline, and malignant components. As a result, a spectrum of molecules of malignant and non-malignant type is shared by each grade of tumor and can appear in the same specimen (
vß6 integrin expression is associated with malignancy, the presence of this integrin in non-homogeneous benign mucinous tumors is not surprising. In addition, mucinous tumors are seldom classified beyond Grade 1. Tumors beyond this grade tend to be placed in an undifferentiated category.
Changes in the expression and/or function of the integrin receptors have been reported in a number of epithelial tumors (v integrins are important in modulating the behavior of epithelial cells (
vß4 integrin, which normally is a component of hemidesmosomes, is lost or exhibits aberrant expression in various cancers (
vß3 integrin is upregulated significantly during the invasive stages of both melanoma and glioblastoma (
vß4 laminin receptor within the cell and the cell membrane in poorly differentiated ovarian carcinomas is changed compared with normal epithelia (
vß4 receptor. Moreover, genetic expression of
5ß1 integrin in Chinese hamster ovary (CHO) cells resulted in suppression of tumor growth in nude mice (
5-deficient CHO cells manifest increased tumorgenicity, suggesting a role for this integrin in cancer progression (
vß6 integrin, triggered by our finding of the expression of this integrin in metastatic ovarian cancer cells.
There is a gradual increase in the expression of vß6 integrin from borderline to malignant tumors. There is also a progression in the intensity of staining from the well-differentiated to the poorly differentiated cancers. This is consistent with increased expression of
vß6 integrin in oral squamous carcinomas (
vß6 function by using inhibitory antibodies results in total abrogation of MMP-9 activation (
vß6 integrin and MMP-9 are linked, and their co-ordinate expression appears to promote invasion by squamous and colon carcinoma cells. Recently, we have also shown that the expression of
vß6 integrin in ovarian cancer cells correlates with enhanced uPA, MMP-2, and MMP-9 secretion and the protease-dependent matrix degradation (
vß6 function results in complete abolishment of matrix degradation (
vß6 integrin in ovarian cancer tissues may be a prerequisite for the in vivo coordinated changes associated with invasion and migration of malignant ovarian cells.
Whether or not vß6 integrin expression in human ovarian cancer is an independent prognostic factor in survival and disease-free period remains to be elucidated. However, because our study demonstrates the absence of
vß6 integrin in normal ovaries and its presence in all subtypes of ovarian cancer, it poses the possibility of being evaluated as a potential initiator of ovarian cancer progression.
![]() |
Footnotes |
---|
1 Present address: Dr. Mark Baker, LumiCyte, Inc., Fremont, CA.
![]() |
Acknowledgments |
---|
We thank the Research Advisory Committee of the Royal Women's Hospital, Melbourne, Ovcare and Jigsaw Women's Fashion Company, and the Jack Brockhoff Foundation, Australia for supporting this work. NA was in receipt of a RoCan Fellowship in Ovarian Cancer and a grant-in-aid from the Anti-Cancer Council of Victoria during the course of the study. The support of the Rotary Club of Williamstown and the Anti-Cancer Council of Victoria is gratefully acknowledged.
Received for publication October 3, 2001; accepted April 10, 2002.
![]() |
Literature Cited |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Agrez M, Chen A, Cone RI, Pytela R, Sheppard D (1994) The alpha v beta 6 integrin promotes proliferation of colon carcinoma cells through a unique region of the beta 6 cytoplasmic domain. J Cell Biol 127:547-556[Abstract]
Agrez M, Gu X, Turton J, Meldrum C, Niu J, Antalis T, Howard EW (1999) The alpha v beta 6 integrin induces gelatinase B secretion in colon cancer cells. Int J Cancer 81:90-97[Medline]
Ahmed N, Pansino F, Baker M, Rice G, Quinn M (2002) Association between alpha v beta 6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer. J Cell Biochem 84:675-686[Medline]
Arihiro K, Kaneko M, Fujii S, Inai K, Yokosaki Y (2000) Significance of alpha 9 beta 1 and alpha v beta 6 integrin expression in breast carcinoma. Breast Cancer 7:19-26[Medline]
Bottini C, Miotti S, Fiorucci S, Facheris P, Menard S, Colnaghi MI (1993) Polarization of the alpha 6 beta 4 integrin in ovarian carcinomas. Int J Cancer 54:261-267[Medline]
Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, Nishimura SL et al. (1995) Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci 108:2241-2251
Breuss JM, Gillett N, Lu L, Sheppard D, Pytela R (1993) Restricted distribution of integrin beta 6 mRNA in primate epithelial tissues. J Histochem Cytochem 41:1521-1527
Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA (1995) Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96:1815-1822[Medline]
Cannistra SA (1993) Cancer of the ovary. N Engl J Med 329:1550-1559
Cannistra SA, Ottensmeier C, Niloff J, Orta B, DiCarlo J (1995) Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer. Gynecol Oncol 58:216-225[Medline]
Clark RA, Ashcroft GS, Spencer MJ, Larjava H, Ferguson MW (1996) Re-epithelialization of normal human excisional wounds is associated with a switch from alpha v beta 5 to alpha v beta 6 integrins. Br J Dermatol 135:46-51[Medline]
Dolo V, D'Ascenzo S, Violini S, Pompucci L, Festuccia C, Ginestra A, Vittorelli ML et al. (1999) Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis 17:131-140[Medline]
Giancotti FG, Ruoslahti E (1990) Elevated levels of the alpha 5 beta 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell 60:849-859[Medline]
Haapasalmi K, Zhang K, Tonnesen M, Olerud J, Sheppard D, Salo T, Kramer R et al. (1996) Keratinocytes in human wounds express alpha v beta 6 integrin. J Invest Dermatol 106:42-48[Abstract]
Hamidi S, Salo T, Kainulainen T, Epstein J, Lerner K, Larjava H (2000) Expression of alpha v beta6 integrin in oral leukoplakia. Br J Cancer 82:1433-1440[Medline]
Hynes RO (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69:11-25[Medline]
Jones J, Sugiyama M, Watt FM, Speight PM (1993) Integrin expression in normal, hyperplastic, dysplastic, and malignant oral epithelium. J Pathol 169:235-243[Medline]
Jones J, Watt FM, Speight PM (1997) Changes in the expression of alpha v integrins in oral squamous cell carcinomas. J Oral Pathol Med 26:63-68[Medline]
Juliano RL, Varner JA (1993) Adhesion molecules in cancer: the role of integrins. Curr Opin Cell Biol 5:812-818[Medline]
Korhonen M, Laitinen L, Ylanne J, Koukoulis GK, Quaranta V, Juusela H, Gould VE et al. (1992) Integrin distributions in renal cell carcinomas of various grades of malignancy. Am J Pathol 141:1161-1171[Abstract]
Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics. CA 49:8-31[Medline]
Larjava H, Haapasalmi K, Salo T, Wiebe C, Uitto VJ (1996) Keratinocyte integrins in wound healing and chronic inflammation of the human periodontium. Oral Dis 2:77-86[Medline]
Liapis H, Adler LM, Wick M, Rader JS (1997) Expression of alpha v beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Hum Pathol 28:443-449[Medline]
Marshall JF, Hart IR (1996) The role of alpha v-integrins in tumour progression and metastasis. Semin Cancer Biol 7:129-138[Medline]
Niu J, Gu X, Turton J, Meldrum C, Howard EW, Agrez M (1998) Integrin-mediated signalling of gelatinase B secretion in colon cancer cells. Biochem Biophys Res Commun 249:287-291[Medline]
O'Toole S, McGuinness E, Sheppard B, Bonnar J (1999) Plasminogen activators and inhibitors in ovarian adenocarcinomas. Int J Gynecol Cancer 9:61-66[Medline]
PujadeLauraine E, Lu H, Mirshahi S, Soria J, Soria C, Bernadou A, Kruithof EK et al. (1993) The plasminogen-activation system in ovarian tumors. Int J Cancer 55:27-31[Medline]
Schreiner C, Fisher M, Hussein S, Juliano RL (1991) Increased tumorigenicity of fibronectin receptor deficient Chinese hamster ovary cell variants. Cancer Res 51:1738-1740[Abstract]
Thomas GJ, Lewis MP, Hart IR, Marshall JF, Speight PM (2000) AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int J Cancer 92:641-650
Thomas GJ, Poomsawat S, Lewis MP, Hart IR, Speight P, Marshall JF (2001) Alphavbeta6 integrin upregulates matrix metalloproteinase 9 and promotes migration of normal oral keratinocytes. J Invest Dermatol 116:898-904
Weinacker A, Chen A, Agrez M, Cone RI, Nishimura S, Wayner E, Pytela R et al. (1994) Role of the integrin alpha v beta 6 in cell attachment to fibronectin. Heterologous expression of intact and secreted forms of the receptor. J Biol Chem 269:6940-6948
Young RH, Clement PB, Scully RE (1999) The ovary. In Sternberg SS, ed. Diagnostic Surgical Pathology. Baltimore, Lippincott Williams & Wilkins, 2307-2394